Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Notes Payables (2016 - 2025)

Marimed (MRMD) has disclosed Notes Payables for 12 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Notes Payables fell 46.85% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 million, a 46.85% decrease, with the full-year FY2024 number at $5.1 million, up 608.99% from a year prior.
  • Notes Payables was $2.3 million for Q3 2025 at Marimed, down from $4.8 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $5.1 million in Q4 2024 to a low of $4856.0 in Q1 2021.
  • A 5-year average of $1.5 million and a median of $537500.0 in 2023 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: tumbled 99.98% in 2021, then surged 6117.65% in 2024.
  • Marimed's Notes Payables stood at $1.4 million in 2021, then surged by 167.66% to $3.8 million in 2022, then crashed by 80.84% to $723000.0 in 2023, then soared by 608.99% to $5.1 million in 2024, then tumbled by 54.68% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Notes Payables are $2.3 million (Q3 2025), $4.8 million (Q1 2025), and $5.1 million (Q4 2024).